Generic Name and Formulations:
Dipivefrin HCl 0.1%; oph. soln; contains benzalkonium chloride.
Indications for PROPINE:
Initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
1 drop every 12 hrs. Transferring from antiglaucoma agents other than epinephrine: on the first day continue previous medication and add 1 drop of Propine in each eye every 12 hours; on the following day, discontinue previous antiglaucoma agent. Transferring from conventional epinephrine therapy: discontinue epinephrine medication and institute Propine regimen. If additional therapy is required, add 1 drop of Propine every 12 hours to other antiglaucoma agents. Concomitant therapy: may add Propine to pilocarpine, carbachol, echothiophate iodide or acetazolamide for difficult to control patients.
Aphakic patients are at increased risk of developing maculopathy; monitor visual acuity closely. Cardiovascular disease. Hypertension. Pregnancy (Cat.B). Nursing mothers.
Local effects (eg, injection, burning, stinging, follicular conjunctivitis, pain, mydriasis, blurry vision, pruritus, adrenochrome deposits in the conjunctiva and cornea), headache, allergic reaction, cardiovascular effects (eg, tachycardia, arrhythmias, hypertension).
Soln—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|